Insider Selling: Elevance Health, Inc. (NYSE:ELV) EVP Sells 14,111 Shares of Stock

Elevance Health, Inc. (NYSE:ELV - Get Free Report) EVP Felicia F. Norwood sold 14,111 shares of Elevance Health stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $533.74, for a total value of $7,531,605.14. Following the transaction, the executive vice president now directly owns 31,460 shares in the company, valued at approximately $16,791,460.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Elevance Health Stock Up 1.1 %

Shares of Elevance Health stock traded up $5.97 during trading hours on Thursday, reaching $539.70. 1,066,967 shares of the company's stock were exchanged, compared to its average volume of 1,064,400. The company has a 50 day moving average of $510.78 and a two-hundred day moving average of $485.44. Elevance Health, Inc. has a fifty-two week low of $412.00 and a fifty-two week high of $542.07. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.54. The stock has a market cap of $125.44 billion, a P/E ratio of 20.40, a P/E/G ratio of 1.18 and a beta of 0.78.

Elevance Health (NYSE:ELV - Get Free Report) last issued its earnings results on Thursday, April 18th. The company reported $10.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.54 by $0.10. The company had revenue of $42.27 billion for the quarter, compared to analysts' expectations of $42.49 billion. Elevance Health had a net margin of 3.64% and a return on equity of 20.62%. Elevance Health's quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $9.46 EPS. On average, sell-side analysts forecast that Elevance Health, Inc. will post 37.25 EPS for the current fiscal year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 25th. Investors of record on Monday, June 10th will be given a dividend of $1.63 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $6.52 annualized dividend and a dividend yield of 1.21%. Elevance Health's dividend payout ratio is 24.64%.

Institutional Trading of Elevance Health

Large investors have recently made changes to their positions in the company. Norges Bank acquired a new stake in Elevance Health in the fourth quarter valued at approximately $1,347,434,000. Massachusetts Financial Services Co. MA acquired a new stake in Elevance Health in the fourth quarter valued at approximately $467,141,000. Canoe Financial LP boosted its position in Elevance Health by 158.1% in the fourth quarter. Canoe Financial LP now owns 844,122 shares of the company's stock valued at $398,054,000 after buying an additional 517,116 shares in the last quarter. Morningstar Investment Services LLC acquired a new stake in Elevance Health in the fourth quarter valued at approximately $239,244,000. Finally, International Assets Investment Management LLC boosted its position in Elevance Health by 45,888.1% in the fourth quarter. International Assets Investment Management LLC now owns 255,694 shares of the company's stock valued at $1,205,750,000 after buying an additional 255,138 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ELV. StockNews.com lowered Elevance Health from a "strong-buy" rating to a "buy" rating in a report on Thursday, January 25th. Barclays lifted their price objective on Elevance Health from $584.00 to $621.00 and gave the stock an "overweight" rating in a research note on Friday, April 19th. Jefferies Financial Group lifted their price objective on Elevance Health from $602.00 to $604.00 and gave the stock a "buy" rating in a research note on Friday, April 19th. Wells Fargo & Company lifted their price objective on Elevance Health from $557.00 to $600.00 and gave the stock an "overweight" rating in a research note on Friday, April 19th. Finally, Royal Bank of Canada lifted their price objective on Elevance Health from $574.00 to $575.00 and gave the stock an "outperform" rating in a research note on Friday, April 19th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $587.42.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.